The 3 analysts offering 12-month price forecasts for Unum Therapeutics Inc have a median target of 1.00, with a high estimate of 4.00 and a low estimate of 0.50. The median estimate represents a +194.20% increase from the last price of 0.34.
The current consensus among 4 polled investment analysts is to Hold stock in Unum Therapeutics Inc. This rating has held steady since March, when it was downgraded from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.30
Reporting Date May 18
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.